A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merrimack Pharmaceuticals
Start Date
June 1, 2016
End Date
March 9, 2018
Administered By
Duke Cancer Institute
Awarded By
Merrimack Pharmaceuticals
Start Date
June 1, 2016
End Date
March 9, 2018